Sanctuary Advisors LLC Buys 9,804 Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Sanctuary Advisors LLC boosted its stake in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 502.8% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 11,754 shares of the specialty pharmaceutical company’s stock after purchasing an additional 9,804 shares during the period. Sanctuary Advisors LLC’s holdings in Jazz Pharmaceuticals were worth $1,310,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the stock. CWA Asset Management Group LLC acquired a new stake in shares of Jazz Pharmaceuticals during the 3rd quarter valued at $3,197,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its stake in shares of Jazz Pharmaceuticals by 135.3% during the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 174,078 shares of the specialty pharmaceutical company’s stock valued at $19,394,000 after purchasing an additional 100,112 shares in the last quarter. Pacer Advisors Inc. grew its holdings in shares of Jazz Pharmaceuticals by 15.3% during the third quarter. Pacer Advisors Inc. now owns 2,099,378 shares of the specialty pharmaceutical company’s stock worth $233,892,000 after purchasing an additional 278,465 shares during the last quarter. Philip James Wealth Mangement LLC acquired a new position in shares of Jazz Pharmaceuticals in the third quarter valued at approximately $830,000. Finally, Thompson Siegel & Walmsley LLC boosted its position in Jazz Pharmaceuticals by 30.6% during the 2nd quarter. Thompson Siegel & Walmsley LLC now owns 721,530 shares of the specialty pharmaceutical company’s stock worth $77,009,000 after buying an additional 168,957 shares during the period. Institutional investors own 89.14% of the company’s stock.

Insider Activity at Jazz Pharmaceuticals

In other news, CEO Bruce C. Cozadd sold 1,000 shares of the business’s stock in a transaction that occurred on Friday, November 1st. The stock was sold at an average price of $110.84, for a total transaction of $110,840.00. Following the completion of the sale, the chief executive officer now owns 428,976 shares in the company, valued at $47,547,699.84. The trade was a 0.23 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, EVP Neena M. Patil sold 3,700 shares of the stock in a transaction on Friday, November 8th. The stock was sold at an average price of $123.41, for a total value of $456,617.00. Following the completion of the transaction, the executive vice president now owns 33,048 shares in the company, valued at approximately $4,078,453.68. This represents a 10.07 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 6,753 shares of company stock valued at $816,289 in the last three months. Corporate insiders own 4.20% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on JAZZ shares. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $140.00 price target on shares of Jazz Pharmaceuticals in a research note on Monday, September 9th. Piper Sandler reaffirmed an “overweight” rating and set a $163.00 target price on shares of Jazz Pharmaceuticals in a report on Thursday, December 12th. TD Cowen decreased their price target on Jazz Pharmaceuticals from $200.00 to $195.00 and set a “buy” rating for the company in a research note on Thursday, November 7th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $179.00 price objective on shares of Jazz Pharmaceuticals in a research note on Tuesday, December 10th. Finally, HC Wainwright reissued a “buy” rating and set a $200.00 target price on shares of Jazz Pharmaceuticals in a research report on Friday, November 22nd. Two investment analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $177.00.

Jazz Pharmaceuticals Price Performance

Shares of NASDAQ JAZZ opened at $122.97 on Friday. The firm has a market capitalization of $7.43 billion, a P/E ratio of 17.32, a P/E/G ratio of 1.02 and a beta of 0.57. The firm’s 50-day moving average price is $118.89 and its 200-day moving average price is $112.73. The company has a current ratio of 4.26, a quick ratio of 3.74 and a debt-to-equity ratio of 1.46. Jazz Pharmaceuticals plc has a 1-year low of $99.06 and a 1-year high of $134.17.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.